

MEDIA RELEASE

Thomson Medical Group Reports Sustained Growth Momentum for 2Q2019

- Revenue grows **7.9%** to S\$57.2 million
- Adjusted EBITDA¹ rises **21.4%** to S\$14.1 million
- Revenue from Hospital Operations and Ancillary Services increased by **11.3%**
- Revenue from Specialised Services up by **2.5%**
- Healthy cash position of **S\$121.3 million**

Financial Highlights	2Q2019 (S\$'000)	2Q2018 (S\$'000)	Change %	1Q2019 (S\$'000)	1Q2018 (S\$'000)	Change %
Revenue	57,150	52,978	7.9%	54,518	52,523	3.8%
Adjusted EBITDA ¹	14,068	11,589	21.4%	13,397	11,751	14.0%
Operating Profit	9,666	8,235	17.4%	9,358	8,087	15.7%
Profit After Tax (from continuing operations)	2,089	2,561	(18.4%)	2,015	4,308	(53.2%)

¹ This number includes the effect from the adoption of new lease accounting which took effect on 1 January 2019. Excluding this effect, the Adjusted EBITDA would have been an increase of 4.1%.

Singapore, 08 August 2019 – SGX Mainboard-listed Thomson Medical Group Limited (“**the Group**”) reported a 7.9% growth in revenue to S\$57.2 million for the second quarter ended 30 June 2019 (“**2Q2019**”).

The increase in revenue arose from higher overall patient load, average bill sizes and greater revenue intensity in the Group’s hospitals and specialist clinics in Singapore and Malaysia.

Adjusted EBITDA rose by 21.4% from S\$11.6 million to S\$14.1 million in 2Q2019 on the back of higher revenue growth and adoption of the new lease accounting. Operating profits continued to show good growth momentum rising 17.4% from S\$8.2 million in 2Q2018 to S\$9.7 million in 2Q2019, underscoring the strength of the Group’s core healthcare business fundamentals.

Compared to the preceding quarter (“**1Q2019**”), the Group’s revenue, adjusted EBITDA and operating profit all improved – up 4.8%, 5.0% and 3.3% respectively.

Group net profit continued to be weighed down by financing costs associated with the takeover of healthcare assets. Net profit after tax was S\$2.1 million in 2Q2019 compared to S\$2.6 million in 2Q2018. This was, however, 3.7% higher than the net profit of S\$2.0 million in 1Q2019. The Group’s consolidated cash position as of 30 June 2019 was S\$121.3 million.

In July 2019, the Group successfully launched a S\$225 million 4.8% 3-year medium term note issue to refinance its existing bank borrowings. This debut bond offering from the Group was well received by investors and was two times oversubscribed. The bond issue has enabled the Company to strengthen its balance sheet and diversify its sources of funding.

The Group continues to grow its operations and expand its core specialities in women and children’s health, fertility, oncology and preventive healthcare and wellness. In Singapore, the Group’s multi-speciality medical centre at Paragon Medical Centre (Thomson Wellth@Paragon) has commenced operations. The Thomson Breast Centre, a one-stop surgical breast centre dedicated to the diagnosis and treatment of all breast-related concerns, has also commenced operations at Thomson Medical Centre, expanding the hospital’s service offerings for women’s health to the next level. In line with the deepening of our core specialities, the hospital will be setting up its Thomson Surgical Centre by year-end.

In Malaysia, expansion works of the new wing with additional capacity for 400 beds at Thomson Hospital Kota Damansara is on schedule. In Johor Bahru, piling works for the new Thomson Iskandar Medical Hub, which will house the 500-bed Iskandariah Hospital, is in progress.

– End –

About Thomson Medical Group Limited

Listed on the Mainboard of the Singapore Exchange, Thomson Medical Group Limited is one of the largest listed healthcare players in the South-East Asian region based on market capitalisation with operations in Singapore and Malaysia.

Established in 1979, the Group's Thomson Medical Pte Ltd is one of the largest private provider of healthcare services for women and children in Singapore. It owns and operates the iconic Thomson Medical Centre and a network of specialist medical clinics and facilities in Singapore.

The Group's operations in Malaysia under TMC Life Sciences Berhad is a multi-disciplinary healthcare company listed on Bursa Malaysia. It operates Thomson Hospital Kota Damansara, a tertiary hospital located in Kota Damansara, and the award-winning TMC Fertility Centre which is the industry leader in assisted reproduction in Malaysia. It also owns the proposed Thomson Iskandar Medical Hub, in Johor Bahru, Malaysia.

For more information, please visit: www.thomsonmedicalgroup.com.

For media enquiries, kindly contact:

Warren Wu

Corporate Communications, Thomson Medical Group Limited

Tel: (+65) 6933 8263

Mobile: (+65) 9170 0175

Email: warrenwu@thomsonmedical.com